222 related articles for article (PubMed ID: 32871800)
1. Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted.
Rossi D; Lippe P; Rocchi MBL; Sarti D; Catalano V; Graziano F; Giordani P; Baldelli A; Fedeli SL; Imperatori L; Laici G; Cappelletti C; Tamburrano T; Bracci R; Alessandroni P
In Vivo; 2020; 34(5):2687-2691. PubMed ID: 32871800
[TBL] [Abstract][Full Text] [Related]
2. Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer.
D'Ascanio M; Pezzuto A; Fiorentino C; Sposato B; Bruno P; Grieco A; Mancini R; Ricci A
Biomed Res Int; 2018; 2018():6278403. PubMed ID: 30225260
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Katsaounis P; Kotsakis A; Agelaki S; Kontopodis E; Agelidou A; Kentepozidis N; Vamvakas L; Christopoulou A; Karachaliou N; Hatzidaki D; Georgoulias V
Cancer Chemother Pharmacol; 2015 Apr; 75(4):821-7. PubMed ID: 25702051
[TBL] [Abstract][Full Text] [Related]
4. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial).
Camerini A; Puccetti C; Donati S; Valsuani C; Petrella MC; Tartarelli G; Puccinelli P; Amoroso D
BMC Cancer; 2015 May; 15():359. PubMed ID: 25943747
[TBL] [Abstract][Full Text] [Related]
5. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
Platania M; Pasini F; Porcu L; Boeri M; Verderame F; Modena Y; Del Conte A; Nichetti F; Garassino MC; Martinetti A; Sottotetti E; Cavanna L; Vattemi E; Pozzessere D; Bertolini A; Irtelli L; Verri C; Sozzi G; Proto C; Pastorino U; Torri V; Fraccon AP; Spinnato F; Signorelli D; Lo Russo G; Tuzi A; Gallucci R; Cinieri S; Mencoboni M; Antonelli P; Giacomelli L; de Braud F
Lung Cancer; 2019 Jun; 132():17-23. PubMed ID: 31097088
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of single-agent oral vinorelbine in patients with pretreated advanced non-small-cell lung cancer.
Rossi D; Catalano V; Alessandroni P; Fedeli A; Fedeli SL; Giordani P; Baldelli AM; Casadei V; Ceccolini M; Ugolini M; Dennetta D; Catalano G
Clin Lung Cancer; 2007 May; 8(6):382-5. PubMed ID: 17562239
[TBL] [Abstract][Full Text] [Related]
7. Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.
Banna GL; Camerini A; Bronte G; Anile G; Addeo A; Rundo F; Zanghì G; Lal R; Libra M
Anticancer Res; 2018 Jun; 38(6):3689-3697. PubMed ID: 29848729
[TBL] [Abstract][Full Text] [Related]
8. Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.
Mencoboni M; Filiberti RA; Taveggia P; Del Corso L; Del Conte A; Covesnon MG; Puccetti C; Donati S; Auriati L; Amoroso D; Camerini A
Anticancer Res; 2017 Jun; 37(6):3189-3194. PubMed ID: 28551663
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection.
Provencio M; Majem M; Guirado M; Massuti B; de Las Peñas R; Ortega AL; Dómine M; Marsé R; Sala MÁ; Paredes A; Morán T; Vázquez S; Coves J; Larriba JLG; Sánchez JM; Vicente D; Farré N; Fornos LF; Zapata I; Franco F; Serna-Blasco R; Romero A; Isla D
Lung Cancer; 2021 Mar; 153():25-34. PubMed ID: 33453470
[TBL] [Abstract][Full Text] [Related]
10. Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis.
Camerini A; Banna GL; Cinieri S; Pezzuto A; Mencoboni M; Rosetti F; Figueiredo A; Rizzo P; Ricci A; Langenhoven L; Santo A; Addeo A; Amoroso D; Barata F
Clin Transl Oncol; 2019 Jun; 21(6):790-795. PubMed ID: 30448956
[TBL] [Abstract][Full Text] [Related]
11. Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial.
Camerini A; Morabito A; Montanino A; Bernabé R; Grossi F; Ramlau R; Ciuleanu TE; Ceresoli GL; Pasello G; de Marinis F; Bosch-Barrera J; Laundreau P; Gautier S; Ta Thanh Minh C; Kowalski D
ESMO Open; 2021 Apr; 6(2):100051. PubMed ID: 33611164
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
[TBL] [Abstract][Full Text] [Related]
13. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V
Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
[TBL] [Abstract][Full Text] [Related]
14. Metronomic oral vinorelbine in a real-world population of advanced non-small cell lung cancer patients.
Estevinho F; Gomes R; Hasmucrai D; Barata F
Pulmonology; 2022; 28(5):368-375. PubMed ID: 33032956
[TBL] [Abstract][Full Text] [Related]
15. An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.
Pujol JL; Coffy A; Camerini A; Kotsakis A; Mencoboni M; Gusella M; Pasini F; Pezzuto A; Banna GL; Bilir C; Samantas E; Barlesi F; Roch B; Guillou A; Daurès JP
PLoS One; 2019; 14(8):e0220988. PubMed ID: 31430345
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
[TBL] [Abstract][Full Text] [Related]
17. Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.
Barlesi F; Imbs DC; Tomasini P; Greillier L; Galloux M; Testot-Ferry A; Garcia M; Elharrar X; Pelletier A; André N; Mascaux C; Lacarelle B; Cheikh RE; Serre R; Ciccolini J; Barbolosi D
Oncotarget; 2017 Jul; 8(29):47161-47166. PubMed ID: 28525370
[TBL] [Abstract][Full Text] [Related]
18. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.
Briasoulis E; Aravantinos G; Kouvatseas G; Pappas P; Biziota E; Sainis I; Makatsoris T; Varthalitis I; Xanthakis I; Vassias A; Klouvas G; Boukovinas I; Fountzilas G; Syrigos KN; Kalofonos H; Samantas E
BMC Cancer; 2013 May; 13():263. PubMed ID: 23718900
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group.
Kontopodis E; Hatzidaki D; Varthalitis I; Kentepozidis N; Giassas S; Pantazopoulos N; Vardakis N; Rovithi M; Georgoulias V; Agelaki S
J Chemother; 2013 Feb; 25(1):49-55. PubMed ID: 23433445
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Vergnenegre A; Monnet I; Ricordel C; Bizieux A; Curcio H; Bernardi M; Corre R; Guisier F; Hominal S; Le Garff G; Bylicki O; Locher C; Geier M; Chouaïd C; Robinet G;
Lung Cancer; 2023 Apr; 178():191-197. PubMed ID: 36868180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
